Ftse Mib
36.218,98
0,00%
DAX
21.428,24
-1,30%
S&P 500
5.994,57
-0,76%
NASDAQ
19.391,96
-1,20%
Bitcoin
99.578,47
-1,82%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NewAmsterdam Pharma Company NV (NAMSW) NewAmsterdam Pharma Company NV (NAMSW) Notizie

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NAMSW
DataOraFonteTitoloSimboloCompagnia
29/01/202514:00GlobeNewswire Inc.NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech ConferenceNASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/01/202522:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/01/202514:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/01/202514:00GlobeNewswire Inc.NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/01/202521:38GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/01/202523:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
07/01/202522:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NAMSWNewAmsterdam Pharma Company NV
13/12/202423:16GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
13/12/202412:33Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/12/202403:37GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
12/12/202401:57Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/12/202422:34GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
10/12/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
20/11/202413:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFHNASDAQ:NAMSWNewAmsterdam Pharma Company NV
18/11/202421:20GlobeNewswire Inc.NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/11/202414:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
06/11/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
28/10/202421:30GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in NovemberNASDAQ:NAMSWNewAmsterdam Pharma Company NV
30/08/202414:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in SeptemberNASDAQ:NAMSWNewAmsterdam Pharma Company NV
07/08/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
29/07/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
26/07/202422:01GlobeNewswire Inc.NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
18/07/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of DirectorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
08/07/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk FactorsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
11/06/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark OfficeNASDAQ:NAMSWNewAmsterdam Pharma Company NV
29/05/202414:00GlobeNewswire Inc.NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in JuneNASDAQ:NAMSWNewAmsterdam Pharma Company NV
21/05/202414:00GlobeNewswire Inc.NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical MeetingsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202422:18Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202422:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
09/05/202414:00GlobeNewswire Inc.NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NAMSW

La tua Cronologia

BIT
UC8ALN
Unicredit Bank
BIT
I10190
XS2847640724 20340814 0.01
BIT
Q00571
Leonteq Securities
BIT
S25037
SG ISSUER
BIT
NSCIT1218808
International Bank for R...
BIT
UC45YW
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci